Correction to: ERG oncogene modulates prostaglandin signaling in prostate cancer cells (Cancer Biology & Therapy, (2011), 11, 4, (410-417), 10.4161/cbt.11.4.14180);ERG oncogene modulates prostaglandin signaling in prostate cancer cells

Cancer Biology and Therapy

Volumn 11, Issue 4, 2011, Pages 410-417

  Mohamed, Ahmed A ^a   Tan, Shyh Han ^a   Sun, Chen ^a   Shaheduzzaman, Syed ^a   Hu, Ying ^a   Petrovics, Gyorgy ^a   Chen, Yongmei ^a   Sesterhenn, Isabell A ^b,c   Li, Hua ^a   Sreenath, Taduru ^a   McLeod, David G ^a,c,d   Dobi, Albert ^a,c   Srivastava, Shiv ^a,c  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

^c United States Military Cancer Institute   (United States)

^d WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

Cancer; ERG; ETS; HPGD; Inflammation; Oncogene; Prostaglandin; Prostate; TMPRSS2; Tumor suppressor

Indexed keywords

15 HYDROXYPROSTAGLANDIN DEHYDROGENASE; ONCOPROTEIN; PROSTAGLANDIN; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN E2; TRANSCRIPTION FACTOR ERG; TUMOR SUPPRESSOR PROTEIN; UROKINASE;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; ARTICLE; CANCER CELL; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; GENE ACTIVATION; GENE FUSION; HUMAN; HUMAN CELL; MALE; NUCLEOTIDE SEQUENCE; ONCOGENE; PROMOTER REGION; PROSTAGLANDIN SIGNALING; PROSTATE CANCER; PROTEIN DEPLETION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR GROWTH; UPREGULATION;

EID: 79951838697     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.1080/15384047.2024.2350871     Document Type: Erratum

References (49)

1. Petrovics G, Liu A, Shaheduzzaman S, Furusato B, Sun C, Chen Y, et al. Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome. Oncogene 2005; 24:3847-52. (Pubitemid 40826884)
2. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005; 310:644-8. (Pubitemid 41528150)
3. Kumar-Sinha C, Tomlins SA, Chinnaiyan AM. Recurrent gene fusions in prostate cancer. Nat Rev Cancer 2008; 8:497-511.
4. Demichelis F, Fall K, Perner S, Andren O, Schmidt F, Setlur SR, et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 2007; 26:4596-9. (Pubitemid 47037039)
5. Sun C, Dobi A, Mohamed A, Li H, Thangapazham RL, Furusato B, et al. TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation. Oncogene 2008; 27:5348-53.
6. Gopalan A, Leversha MA, Satagopan JM, Zhou Q, Al-Ahmadie HA, Fine SW, et al. TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy. Cancer Res 2009; 69:1400-6.
7. Rostad K, Mannelqvist M, Halvorsen OJ, Oyan AM, Bo TH, Stordrange L, et al. ERG upregulation and related ETS transcription factors in prostate cancer. Int J Oncol 2007; 30:19-32.
8. Perner S, Mosquera JM, Demichelis F, Hofer MD, Paris PL, Simko J, et al. TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. Am J Surg Pathol 2007; 31:882-8. (Pubitemid 47165141)
9. Mehra R, Tomlins SA, Yu J, Cao X, Wang L, Menon A, et al. Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer. Cancer Res 2008; 68:3584-90.
10. Hu Y, Dobi A, Sreenath T, Cook C, Tadase AY, Ravindranath L, et al. Delineation of TMPRSS2-ERG splice variants in prostate cancer. Clin Cancer Res 2008; 14:4719-25.
11. Rickman DS, Pflueger D, Moss B, VanDoren VE, Chen CX, de la Taille A, et al. SLC45A3-ELK4 is a novel and frequent erythroblast transformation-specific fusion transcript in prostate cancer. Cancer Res 2009; 69:2734-8.
12. Furusato B, Gao CL, Ravindranath L, Chen Y, Cullen J, McLeod DG, et al. Mapping of TMPRSS2-ERG fusions in the context of multi-focal prostate cancer. Mod Pathol 2008; 21:67-75. (Pubitemid 351172158)
13. Pflueger D, Rickman DS, Sboner A, Perner S, LaFargue CJ, Svensson MA, et al. N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer. Neoplasia 2009; 11:804-11.
14. Carver BS, Tran J, Gopalan A, Chen Z, Shaikh S, Carracedo A, et al. Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet 2009; 41:619-24.
15. Klezovitch O, Risk M, Coleman I, Lucas JM, Null M, True LD, et al. A causal role for ERG in neoplastic transformation of prostate epithelium. Proc Natl Acad Sci USA 2008; 105:2105-10. (Pubitemid 351439472)
16. Zong Y, Xin L, Goldstein AS, Lawson DA, Teitell MA,Witte ON. ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells. Proc Natl Acad Sci USA 2009; 106:12465-70.
17. Tomlins SA, Laxman B, Varambally S, Cao X, Yu J, Helgeson BE, et al. Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia 2008; 10:177-88. (Pubitemid 351240884)
18. King JC, Xu J, Wongvipat J, Hieronymus H, Carver BS, Leung DH, et al. Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat Genet 2009; 41:524-6.
19. +-linked 15-hydroxyprostaglandin dehydrogenase: structure and biological functions. Curr Pharm Des 2006; 12:955-62.
20. Heighway J, Knapp T, Boyce L, Brennand S, Field JK, Betticher DC, et al. Expression profiling of primary non-small cell lung cancer for target identification. Oncogene 2002; 21:7749-63. (Pubitemid 35398821)
21. Sugimoto Y, Narumiya S. Prostaglandin E receptors. J Biol Chem 2007; 282:11613-7. (Pubitemid 47100657)
22. Myung SJ, Rerko RM, Yan M, Platzer P, Guda K, Dotson A, et al. 15-Hydroxyprostaglandin dehydrogenase is an in vivo suppressor of colon tumorigenesis. Proc Natl Acad Sci USA 2006; 103:12098-102. (Pubitemid 44215817)
23. Wolf I, O'Kelly J, Rubinek T, Tong M, Nguyen A, Lin BT, et al. 15-hydroxyprostaglandin dehydrogenase is a tumor suppressor of human breast cancer. Cancer Res 2006; 66:7818-23. (Pubitemid 44289243)
24. Wang D, DuBois RN. Pro-inflammatory prostaglandins and progression of colorectal cancer. Cancer Lett 2008; 267:197-203.
25. Chaudry AA, Wahle KW, McClinton S, Moffat LE. Arachidonic acid metabolism in benign and malignant prostatic tissue in vitro: effects of fatty acids and cyclooxygenase inhibitors. Int J Cancer 1994; 57:176-80. (Pubitemid 24144205)
26. Ma X, Kundu N, Rifat S, Walser T, Fulton AM. Prostaglandin E receptor EP4 antagonism inhibits breast cancer metastasis. Cancer Res 2006; 66:2923-7.
27. Quidville V, Segond N, Lausson S, Frenkian M, Cohen R, Jullienne A. 15-Hydroxyprostaglandin-dehydrogenase is involved in anti-proliferative effect of non-steroidal anti-inflammatory drugs COX-1 inhibitors on a human medullary thyroid carcinoma cell line. Prostaglandins Other Lipid Mediat 2006; 81:14-30. (Pubitemid 44403167)
28. Frenkian M, Segond N, Pidoux E, Cohen R, Jullienne A. Indomethacin, a COX inhibitor, enhances 15-PGDH and decreases human tumoral C cells proliferation. Prostaglandins 2001; 65:11-20. (Pubitemid 32378799)
29. Chi X, Freeman BM, Tong M, Zhao Y, Tai HH. 15-Hydroxyprostaglandin dehydrogenase (15-PGDH) is upregulated by flurbiprofen and other non-steroidal anti-inflammatory drugs in human colon cancer HT29 cells. Arch Biochem Biophys 2009; 487:139-45.
30. Tseng-Rogenski S, Lee IL, Gebhardt D, Fischer SM, Wood C, Park JM, et al. Loss of 15-hydroxyprostaglandin dehydrogenase expression disrupts urothelial differentiation. Urology 2008; 71:346-50.
31. Eruslanov E, Kaliberov S, Daurkin I, Kaliberova L, Buchsbaum D, Vieweg J, et al. Altered expression of 15-hydroxyprostaglandin dehydrogenase in tumor-infiltrated CD11b myeloid cells: a mechanism for immune evasion in cancer. J Immunol 2009; 182:7548-57.
32. De Marzo AM, Nakai Y, Nelson WG. Inflammation, atrophy and prostate carcinogenesis. Urol Oncol 2007; 25:398-400.
33. Greenland KJ, Jantke I, Jenatschke S, Bracken KE, Vinson C, Gellersen B. The human NAD+-dependent 15-hydroxyprostaglandin dehydrogenase gene promoter is controlled by Ets and activating protein-1 transcription factors and progesterone. Endocrinology 2000; 141:581-97. (Pubitemid 32250482)
34. +-dependent 15-hydroxyprostaglandin dehydrogenase gene. J Mol Endocrinol 2003; 31:105-21.
35. 2 pathway mediates icariside II induced apoptosis in human PC-3 prostate cancer cells. Cancer Lett 2009; 280:93-100.
36. Ahmad A, Kong D, Wang Z, Sarkar SH, Banerjee S, Sarkar FH. Downregulation of uPA and uPAR by 3,3′-diindolylmethane contributes to the inhibition of cell growth and migration of breast cancer cells. J Cell Biochem 2009; 108:916-25.
37. Noskova V, Ahmadi S, Asander E, Casslen B. Ovarian cancer cells stimulate uPA gene expression in fibroblastic stromal cells via multiple paracrine and autocrine mechanisms. Gynecol Oncol 2009; 115:121-6.
38. Chen Y, Hughes-Fulford M. Prostaglandin E2 and the protein kinase A pathway mediate arachidonic acid induction of c-fos in human prostate cancer cells. Br J Cancer 2000; 82:2000-6. (Pubitemid 30326462)
39. Perner S, Demichelis F, Beroukhim R, Schmidt FH, Mosquera JM, Setlur S, et al. TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res 2006; 66:8337-41. (Pubitemid 44449140)
40. Nam RK, Sugar L, Wang Z, Yang W, Kitching R, Klotz LH, et al. Expression of TMPRSS2:ERG gene fusion in prostate cancer cells is an important prognostic factor for cancer progression. Cancer Biol Ther 2007; 6:40-5. (Pubitemid 46294173)
41. Shin S, Kim TD, Jin F, van Deursen JM, Dehm SM, Tindall DJ, et al. Induction of prostatic intraepithelial neoplasia and modulation of androgen receptor by ETS variant 1/ETS-related protein 81. Cancer Res 2009; 69:8102-10.
42. Yu J, Mani RS, Cao Q, Brenner CJ, Cao X, Wang X, et al. An integrated network of androgen receptor, polycomb and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell 17:443-54.
43. Hawcroft G, Ko CW,Hull MA. Prostaglandin E2-EP4 receptor signalling promotes tumorigenic behaviour of HT-29 human colorectal cancer cells. Oncogene 2007; 26:3006-19. (Pubitemid 46733647)
44. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Gronberg H, Drake CG, et al. Inflammation in prostate carcinogenesis. Nat Rev Cancer 2007; 7:256-69. (Pubitemid 46486616)
45. Otani T, Yamaguchi K, Scherl E, Du B, Tai HH, Greifer M, et al. Levels of NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase are reduced in inflammatory bowel disease: evidence for involvement of TNFalpha. Am J Physiol Gastrointest Liver Physiol 2006; 290:361-8.
46. Furusato B, Tan SH, Young D, Dobi A, Sun C, Mohamed AA, et al. ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification. Prostate Cancer Prostatic Dis 2010; 13:228-37.
47. Mohamed AA, Tan SH, Mikhalkevich N, Ponniah S, Vasioukhin V, Bieberich CJ, et al. Ets family protein, ERG expression in developing and adult mouse tissues by a highly specific monoclonal antibody. Journal of Cancer 2010; 1:197-208.
48. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25:402-8. (Pubitemid 34164012)
49. Masuda K, Werner T, Maheshwari S, Frisch M, Oh S, Petrovics G, et al. Androgen receptor binding sites identified by a GREF-GATA model. J Mol Biol 2005; 353:763-71. (Pubitemid 41457382)